Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-09-14

FDA Approved: RIFAMPIN — Supplemental Application (Lupin Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved Lupin Pharmaceuticals' supplemental application for Rifampin under the ANDA. The approval indicates changes to the Rifampin product's labeling or i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RIFAMPIN (RIFAMPIN)

Snippet

SUPPL AP for RIFAMPIN (RIFAMPIN)